Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.
Is now the time to buy Vertex Pharmaceuticals? Find out by accessing our full research report, it’s free.
Vertex Pharmaceuticals (VRTX) Q2 CY2026 Highlights:
- Revenue: $3.33 billion vs analyst estimates of $3.19 billion (12.5% year-on-year growth, 4.6% beat)
- Adjusted EPS: $4.73 vs analyst expectations of $4.75 (in line)
- Adjusted Operating Income: $1.42 billion vs analyst estimates of $1.37 billion (42.7% margin, 3.9% beat)
- The company slightly lifted its revenue guidance for the full year to $13.15 billion at the midpoint from $13.03 billion
- Operating Margin: 37.4%, down from 38.8% in the same quarter last year
- Market Capitalization: $121.1 billion
Company Overview
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ: VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Revenue Growth
Reviewing a company’s long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, Vertex Pharmaceuticals’s 13.5% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Vertex Pharmaceuticals’s annualized revenue growth of 10.3% over the last two years is below its five-year trend, but we still think the results were respectable. 
This quarter, Vertex Pharmaceuticals reported year-on-year revenue growth of 12.5%, and its $3.33 billion of revenue exceeded Wall Street’s estimates by 4.6%.
Looking ahead, sell-side analysts expect revenue to grow 5% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. At least the company is tracking well in other measures of financial health.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Vertex Pharmaceuticals has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 38.4%.
Looking at the trend in its profitability, Vertex Pharmaceuticals’s adjusted operating margin decreased by 10.7 percentage points over the last five years, but it rose by 38.6 percentage points on a two-year basis. We like Vertex Pharmaceuticals and hope it can right the ship.
In Q2, Vertex Pharmaceuticals generated an adjusted operating margin profit margin of 42.7%, down 2 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
Vertex Pharmaceuticals’s EPS grew at a remarkable 11.1% compounded annual growth rate over the last five years. However, this performance was lower than its 13.5% annualized revenue growth, telling us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.
We can take a deeper look into Vertex Pharmaceuticals’s earnings quality to better understand the drivers of its performance. As we mentioned earlier, Vertex Pharmaceuticals’s adjusted operating margin declined by 10.7 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q2, Vertex Pharmaceuticals reported adjusted EPS of $4.73, up from $4.52 in the same quarter last year. This print was close to analysts’ estimates. Over the next 12 months, Wall Street expects Vertex Pharmaceuticals’s full-year EPS to stay about the same, moving from $19.03 to $19.02.
Key Takeaways from Vertex Pharmaceuticals’s Q2 Results
We enjoyed seeing Vertex Pharmaceuticals beat analysts’ revenue expectations this quarter. We were also glad its full-year revenue guidance slightly exceeded Wall Street’s estimates. Overall, we think this was a decent quarter with some key metrics above expectations. The stock remained flat at $469.26 immediately after reporting.
So do we think Vertex Pharmaceuticals is an attractive buy at the current price? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).
